Follicular Lymphoma

Risk-Based Management of Follicular Lymphoma

Risk-Based Management of Follicular Lymphoma

Treatment of Follicular Lymphoma

Treatment of Follicular Lymphoma

The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel has shown promising results in patients with diffuse large B-cell lymphoma, primary mediastinal lymphoma, and transformed follicular lymphoma, according to findings presented at the 2017 AACR Annual Meeting.

A majority of patients with relapsed or refractory indolent lymphoma responded to treatment with the PI3K dual-isoform inhibitor copanlisib, according to results from the phase II CHRONOS-1 trial.<br /> &nbsp;

A biologics license application has been submitted for axicabtagene ciloleucel (KTE-C19) as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Patients with lymphoma who are treated with brentuximab vedotin often experience peripheral neuropathy as an adverse event and potentially dose-limiting toxicity. A novel study has shown that, despite the prevalence of this toxicity, these patients report that the better outcomes yielded from treatment with brentuximab vedotin outweigh the risk of neuropathy.&nbsp;

A review of various frontline treatment options in follicular lymphoma and an outline of an algorithm for approaching patients with newly diagnosed follicular lymphoma.

Nathan Fowler, MD, associate professor, University of Texas MD Anderson Cancer Center, discusses managing patients with high-risk follicular lymphoma.